Abstract: Objective To evaluate the efficacy and safety of rh-endostatin（endostar） combined with FOLFIRI regimen in colorectal cancer with hepatic metastasis.
Methods Twenty-nine patients with hepatic metastasis of colorectal cancer were treated with endostar and FOLFIRI regimen from September 2006 to January 2011. Endostar 15mg solved in 500ml normal saline was slowly intravenously dropped from day 1 to day 10 biweekly. FOLFIRI regimen：irinotecan 180mg／m2 iv，d1；leucovorin 400mg／m2 introvenous infusion to match duration of irinotecan infusion，d1；fluorouracil 400mg／m2 iv bolus d1，and then 2400mg／m2 for 46-48h continuously infusion. Every 2 weeks was a cycle. The safety was evaluated after 1 cycle while the efficacy was evaluated after 3-4 cycles.
ResultsAll the cases were evaluated for safety and 27 cases for efficacy with 1 of CR，10 of PR，9 of SD and 7 of PD. The response rate was 40.7％ and disease control rate was 74.1％. The quality of life in 14 cases was improved. The median progress-free survival was 7.8 months（95％CI：5.3-10.2 months）. The adverse effects were mainly in grade 1-2，including hematological toxicities， nausea and vomiting and tardive diarrhea. There was no serious event in cardiovascular system. Conclusion The efficacy and tolerability of endostar plus FOLFIRI regimen in hepatic metastasis of colorectal cancer was good with tolerable adverse effect.